Focused on High Value Cells

Solentim launches new workflow for single cell cloning of stem cells

VIPS™ + MatriClone™ combination ensures high efficiency seeding of hiPSCs with high viability Solentim, the global leader for solutions to create, isolate and characterize the highest value cells for the development of new biological medicines, yesterday launched a dedicated new workflow for single cell cloning of human induced pluripotent stem cells (hiPSCs). A combination of Solentim’s VIPS™ (verified in-situ plate seeding) instrument …

Read more Solentim launches new workflow for single cell cloning of stem cells

Solentim will present at Cell Series UK Virtual, the 9th Annual Cell Culture and Bioprocessing Conference

Solentim, the global leader for solutions to create, isolate and characterize the highest value cells for the development of new biological medicines, is pleased to present at Oxford Global’s 9th Annual Cell Culture and Bioprocessing Virtual Conference on the 6-7th October 2020. Dr Ian Taylor, Chief Business Officer at Solentim, will be speaking on Day 1 (6th October 2020), …

Read more Solentim will present at Cell Series UK Virtual, the 9th Annual Cell Culture and Bioprocessing Conference

Australian Institute for Bioengineering and Nanotechnology adopts Solentim Cell Metric for rapid vaccine program

The Australian Institute for Bioengineering and Nanotechnology (AIBN) at the University of Queensland has adopted the market-leading Cell Metric® whole well imaging system from Solentim to support its Rapid Response Vaccine Pipeline. The UQ team was funded by Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership launched in 2017 to develop vaccines to stop …

Read more Australian Institute for Bioengineering and Nanotechnology adopts Solentim Cell Metric for rapid vaccine program

Continued growth and progress for Solentim: 2019/2020 highlights

Solentim, the world leader in instruments and workflow solutions to create, isolate and characterize the highest value cells for the development of new biological medicines and therapies reports another record year for the 12 months to June 2020. Solentim has achieved record revenue growth from instrument sales and service support, with particular strength in the …

Read more Continued growth and progress for Solentim: 2019/2020 highlights

Neil Pomeroy joins Solentim as new Research and Development Director

We are delighted to announce that Neil Pomeroy has joined the company as Research and Development (R&D) Director, bringing with him a wealth of experience and knowledge to drive the development of our product ecosystem. Neil will be working closely with the team to bring our existing instruments to new markets, and accelerating the development …

Read more Neil Pomeroy joins Solentim as new Research and Development Director

Solentim Turns 10: Celebrating a decade of progress and pioneering advances

Solentim is delighted to celebrate its 10-year anniversary today. Despite the uncertain times we currently live in, Solentim continues to forge ahead, and today celebrates another successful year, and a decade of growth and progress. For all of this success we thank our staff, past and present, and all our customers Global operation Over the …

Read more Solentim Turns 10: Celebrating a decade of progress and pioneering advances

Translate »